БАО Мин (US),ХЭРЭРИ Оливье Альфред (CH),ЯРАЙС Ангелика М. (US),ШМИДТ Йоханнес Ф. (CH),ЧЖАН Сяопин (US),ТЕРАО Кимио (JP)
申请号：
RU2013126477/15
公开号：
RU2013126477A
申请日:
2011.11.07
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating an IL-6-mediated disease in a patient, comprising subcutaneous administration of an anti-IL-6 receptor antibody (IL-6R) to a patient, wherein the anti-IL-6R antibody is administered in a fixed dose of 162 mg per dose. The method of claim 1, wherein a fixed dose is administered every week or every two weeks. The method of claim 1, wherein the IL-6-mediated disease is selected from the group consisting of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis, and Castellman’s disease. The method of claim 1, wherein the IL-6-mediated disease is rheumatoid arthritis (RA). The method of claim 4, wherein the RA patient exhibits an insufficient response to the DMARD. The method of claim 4, wherein the RA patient exhibits an insufficient response to the TNF inhibitor. The method of claim 4, wherein the RA patient is a patient who has not previously received methotrexate (MTX) or has stopped taking MTX. The method of claim 1, further comprising administering to the patient one or more additional drugs that treat an IL-6-mediated disease. The method of claim 8, wherein the additional drug is selected from the group consisting of: immunosuppressive drugs, non-steroidal anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs (DMARD), methotrexate (MTX), antibodies against B-cell surface markers antibodies against CD20, rituximab, TNF inhibitors, corticosteroids and costimulatory modifiers. 10. The method of claim 9, wherein the additional drug is selected from the group consisting of non-biological DMARD, NSAIDs and corticosteroids. The method of claim 1, wherein the anti-IL-6R antibody is t1. Способ лечения IL-6-опосредованного заболевания у пациента, включающий подкожное введение антитела против рецептора IL-6 (IL-6R) пациенту, где антитело против IL-6R вводят в виде фиксированной дозы 162 мг на дозу.2. Способ по п.1, где фиксированную дозу вводят каждую неделю или каждые две недели.3. Способ по п.1, где I
